Search | Clinical Trials Finder

Conditions: Skin Diseases, Infectious
Interventions: Culture; Procedure
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Kidney Cancer
Interventions: dactinomycin, filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2006
U.S. locations: 206
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Age-Related Macular Degeneration
Interventions: ASP7317, tacrolimus, trimethoprim-sulfamethoxazole, Acyclovir, Nystatin; Drug
Lead sponsor: Astellas Institute for Regenerative Medicine; Industry
Eligibility: 50 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimethoprim, Sulfamethoxazole, Leucovorin calcium; Drug
Lead sponsor: Lederle Laboratories; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypospadias
Interventions: Septra; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 6 Months to 2 Years · Male only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Skin Diseases, Infectious
Interventions: Trimethoprim-sulfamethoxazole, Placebo group; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 3 Months to 18 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions: bleomycin sulfate, recombinant interferon alfa, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methotrexate, prednisone, vincristine sulfate, conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 15 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2011
U.S. locations: 86
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more

Conditions: End-Stage Renal Disease
Interventions: Daclizumab, Methylprednisolone/prednisone, Mycophenolate mofetil, Sirolimus, Bactrim, Ganciclovir, Lipitor; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 21 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Osteomyelitis
Interventions: oral antibiotics, intravenous antibiotics; Drug · Procedure
Lead sponsor: Julio Ramirez; Other
Eligibility: 18 Years to 100 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Staphylococcal Infection
Interventions: Cephalexin, Clindamycin, Placebo, Trimethoprim-sulfamethoxazole; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 2,265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 5
States / cities: Phoenix, Arizona • Sylmar, California • Baltimore, Maryland + 2 more

Conditions: Kidney Stones
Interventions: ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin; Drug
Lead sponsor: University of British Columbia; Other
Eligibility: 19 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 11
States / cities: Scottsdale, Arizona • San Diego, California • Baltimore, Maryland + 8 more

Conditions: Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer, Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Cervical Small Cell Carcinoma, Stage III Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
Interventions: Axalimogene filolisbac; Biological
Lead sponsor: Advaxis, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Augusta, Georgia • Charlottesville, Virginia

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 1 Day and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Stress Urinary Incontinence
Interventions: Bactrim or Macrobid, Placebo; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Immune Checkpoint Inhibitor-Related Colitis
Interventions: Vedolizumab 300 MG Injection [Entyvio], Prednisone (and methylprednisolone), Prednisone Taper, Placebo Prednisone Capsules, Placebo Vedolizumab, Sulfamethoxazole-Trimethoprim, Placebo for Sulfamethoxazole-Trimethoprim; Drug · Other
Lead sponsor: Shilpa Grover, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Abscess Soft Tissue, Methicillin-resistant Staphylococcus Aureus (MRSA) Infection, Skin Abscess
Interventions: Oral Clindamycin; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 1 Month to 17 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Bacterial Infections
Interventions: [18F]fluoropropyl-trimethoprim; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Vesicoureteral Reflux, Urinary Tract Infections
Interventions: Trimethoprim-Sulfamethoxazole, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Months to 71 Months
Enrollment: 607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 19
States / cities: Birmingham, Alabama • Wilmington, Delaware • Washington D.C., District of Columbia + 16 more

Conditions: Erectile Dysfunction, Penile Prosthesis Infection
Interventions: Doxycycline, Ciprofloxacin, Augmentin, Bactrim; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 35 Years to 90 Years · Male only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Urinary Tract Infections, Stress Urinary Incontinence, Urinary Incontinence
Interventions: Bactrim (800/160 mg), Keflex (500 mg), Cipro (250 mg), or Macrobid (100mg); Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Recurrent Urinary Tract Infection
Interventions: Lactobacillus reuteri DSM 17938, trimethoprim/sulfamethoxazole; Dietary Supplement · Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 3 Months to 17 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Urinary Tract Infection
Interventions: TMP/SMX, Fosfomycin; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Rhinosinusitis (Diagnosis)
Interventions: Saline Nasal, Budesonide Nasal, Topical Antibacterial (Product); Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: HIV Infections
Interventions: Sulfamethoxazole-Trimethoprim, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Effective Antibiotic Treatment of MRSA

Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome

Antibiotic Use Following Distal and Mid-shaft Hypospadias Repair

Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management

SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

Pediatric Kidney Transplant Without Calcineurin Inhibitors

Patients Response to Early Switch To Oral:Osteomyelitis Study

Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"

Struvite Stones Antibiotic Study

Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer

An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine

Assessing the Utility of Prophylactic Antibiotics at Time of Urethral Bulking Using Bulkamid (Bulkamid Study)

Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial

Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Abscess

[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects

Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)

Collaborative Urological Prosthetics Investigation Directive Research Group

Prophylactic Antibiotics for Outpatient Urethral Bulking

Probiotics for Girls With Recurring Urinary Tract Infections

Single Dose Monurol for Treatment of Acute Cystitis

Comparison of Topical Therapies in Post op Endoscopic Sinus Surgery Patients

Evaluation of the Interaction Between Low Dose Sulfamethoxazole-Trimethoprim and Zidovudine